Conjugation of the target antigen with carrier proteins is also a development strategy for vaccines, such as conjugate vaccines. Binding with carrier proteins can enhance the immunogenicity of vaccines. Currently, approved carrier proteins on the market include diphtheria toxoid (DT), non-toxic mutant of diphtheria toxin CRM197, tetanus toxoid (TT), etc.
With a powerful process development platform, biosafety level BSL-1 and BSL-2 workshops, and a GMP quality system, Yaohai Bio-Pharma can provide customers with a one-stop solution from microbial strain development to GMP production of carrier proteins.
We deliver gram-to-kilogram-scale carrier proteins that meet quality standards, as well as GMP production records and testing reports to our customers.
Approved conjugated vaccines include the following carrier proteins (non-recombinant):
Protein Types
|
Carrier Proteins
|
Strain Types
|
Platform
|
Carrier protein, extracted
|
Diphtheria toxin non-toxic mutants CRM197
|
Corynebacterium diphtheriae
|
Microbial fermentation systems
Centrifugation and homogenization equipment
High/low-pressure chromatography systems
Conjugate reaction tank
Biosafety Level: BSL-2
GMP quality system
|
Diphtheria toxoid (DT)
|
Corynebacterium diphtheriae
|
Tetanus toxoid (TT)
|
Clostridium tetani
|
Meningococcal outer membrane protein complex (OMPC)
|
Neisseria meningitidis
|
Other carrier proteins from microbial sources (BSL-1, BSL-2)
|
Related services: Recombinant Carrier Protein CDMO Solutions.
|
Carrier Protein Drug Product Process
Deliverable
Grade |
Deliverables |
Specification |
Applications |
GMP, BSL-1/BSL-2 |
Intermediate substance |
Bacteria derived carried protein |
Conjugated vaccine production materials |
Vaccine finished product |
Lyophilized powder |
Investigational new drug (IND),
Clinical trial authorisation (CTA),
Clinical trial supply,
Biologic license application (BLA),
Commercial supply
|